Inflammatory bowel diseases (IBD) represent an increasing clinical challenge, particularly in the pediatric population. It is estimated that up to one in four patients with IBD is a child or adolescent. The growing number of diagnoses and the limitations of standard therapy have drawn increasing attention to supportive treatment strategies, including components that affect gut microbiota and intestinal barrier integrity, such as sodium butyrate.
IBD is an immune-mediated condition characterized by periods of remission and flare-ups. It includes, among others, Crohn’s disease and ulcerative colitis. The symptoms of these diseases are relatively nonspecific, which likely contributes to many cases remaining undiagnosed. Common symptoms include abdominal pain, diarrhea, weight loss, fatigue, and fever. In Crohn’s disease, inflammation can involve the full thickness of the intestinal wall and occur in a segmental pattern, with potential complications such as fistulas and abscesses. In contrast, ulcerative colitis affects only the colon, beginning in the rectum and spreading continuously to other segments. A hallmark symptom is recurrent diarrhea, often with blood.
A key factor in the pathogenesis of IBD is gut dysbiosis. The gut microbiota plays a crucial role in the functioning of the body, including the regulation of the immune system, which is why it is strongly linked to IBD. In the colon, bacteria produce butyric acid, a short-chain fatty acid (SCFA) that serves as a primary energy source for colonocytes. Adequate levels of butyrate support proper epithelial function and may help regulate immune responses, including modulation of pro-inflammatory cytokine production and the activity of macrophages, dendritic cells, and T lymphocytes. Butyrate deficiency may be associated with weakening of the intestinal barrier and increased inflammation, which may contribute to disturbances observed in IBD.
Researchers in Romania evaluated the potential of sodium butyrate as an adjunct element to standard therapy in a randomized clinical trial involving 88 patients aged 7–18 years with Crohn’s disease and ulcerative colitis. The study lasted 12 weeks, and participants were randomly assigned to two groups: Group A received standard IBD pharmacotherapy plus 150 mg of microencapsulated sodium butyrate, while Group B received standard therapy with a placebo instead of sodium butyrate.
The study assessed the following parameters:
- The proportion of patients experiencing relapse
- Inflammatory markers: CRP (a systemic inflammation marker) and fecal calprotectin (an intestinal inflammation marker)
- Disease activity indices: PUCAI for pediatric ulcerative colitis and PCDAI for pediatric Crohn’s disease, evaluated at baseline, after 8 weeks, and at the end of the study (12 weeks)
In the sodium butyrate group, a higher proportion of patients remaining in remission was observed compared to the placebo group. Additionally, a reduction in inflammatory markers such as CRP and fecal calprotectin was observed, with comparable baseline values in both groups. Differences in clinical disease activity indices (PUCAI, PCDAI) showed a trend favoring the supplemented group, though not all reached statistical significance. Further studies with larger patient populations and longer follow-up are warranted to confirm long-term efficacy.
The results suggest a potential beneficial effect of sodium butyrate on selected parameters related to inflammation and disease course in children with IBD. It should be noted, however, that these observations are based on clinical study conditions and require further confirmation. Due to its stable formulation and applicability in various formulations, microencapsulated sodium butyrate represents an interesting ingredient for products aimed at supporting gut function and microbiota balance.
